Molecular Partners AG Cash Flow Conversion Efficiency

Latest as of June 2026: -0.181x

Molecular Partners AG cash flow conversion efficiency. Based on the latest financial reports, Molecular Partners AG (MOLN) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-10.61 Million ≈ $-13.41 Million USD) by net assets (CHF58.54 Million ≈ $74.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Molecular Partners AG (2013–2025)

Cash flow conversion efficiency of Molecular Partners AG from 2013 to 2025. This chart illustrates how Molecular Partners AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Molecular Partners AG stock price today for real-time trading data and today's change.

Molecular Partners AG Cash Flow Conversion Ratio Explained

Molecular Partners AG cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Molecular Partners AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Molecular Partners AG ranked by their cash flow conversion efficiency. Also see MOLN company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
ReposiTrak NYSE:TRAK	0.041x
FortuneX Acquisition Corporation Ordinary shares NASDAQ:FXAC	N/A
APM Automotive Holdings Bhd KLSE:5015	0.010x
Futurewave Acquisition Corporation Ordinary Shares NASDAQ:FWAC	N/A
Donegal Group B Inc NASDAQ:DGICB	0.016x
Jyoti Structures Limited NSE:JYOTISTRUC	-0.292x
Thai Metal Drum Manufacturing Public Company Limited BK:TMD	-0.001x
PVP Ventures Limited NSE:PVP	-0.055x

Annual Cash Flow Conversion Efficiency for Molecular Partners AG (2013–2025)

The table below shows the annual cash flow conversion efficiency of Molecular Partners AG from 2013 to 2025. Review Molecular Partners AG (MOLN) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CHF80.33 Million ≈ $101.56 Million	CHF-49.53 Million ≈ $-62.62 Million	-0.617x	-47.39%
2024-12-31	CHF141.64 Million ≈ $179.07 Million	CHF-59.25 Million ≈ $-74.91 Million	-0.418x	-25.08%
2023-12-31	CHF176.43 Million ≈ $223.05 Million	CHF-59.01 Million ≈ $-74.60 Million	-0.334x	-166.33%
2022-12-31	CHF235.17 Million ≈ $297.31 Million	CHF118.57 Million ≈ $149.90 Million	0.504x	+159.47%
2021-12-31	CHF107.29 Million ≈ $135.64 Million	CHF-90.95 Million ≈ $-114.99 Million	-0.848x	-213.61%
2020-12-31	CHF107.22 Million ≈ $135.56 Million	CHF-28.98 Million ≈ $-36.64 Million	-0.270x	-1130.82%
2019-12-31	CHF54.14 Million ≈ $68.45 Million	CHF-1.19 Million ≈ $-1.50 Million	-0.022x	+95.26%
2018-12-31	CHF91.70 Million ≈ $115.94 Million	CHF-42.47 Million ≈ $-53.70 Million	-0.463x	-35.09%
2017-12-31	CHF116.73 Million ≈ $147.58 Million	CHF-40.02 Million ≈ $-50.60 Million	-0.343x	-31.60%
2016-12-31	CHF135.79 Million ≈ $171.68 Million	CHF-35.38 Million ≈ $-44.73 Million	-0.261x	-249.27%
2015-12-31	CHF151.79 Million ≈ $191.91 Million	CHF26.50 Million ≈ $33.50 Million	0.175x	+328.68%
2014-12-31	CHF148.48 Million ≈ $187.72 Million	CHF-11.33 Million ≈ $-14.33 Million	-0.076x	+72.91%
2013-12-31	CHF48.32 Million ≈ $61.08 Million	CHF-13.61 Million ≈ $-17.21 Million	-0.282x	--

About Molecular Partners AG

SW:MOLN Switzerland Biotechnology

Market Cap

$134.63 Million

CHF106.49 Million CHF

Market Cap Rank

#18107 Global

#184 in Switzerland

Share Price

CHF2.78

Change (1 day)

-3.81%

52-Week Range

CHF2.78 - CHF3.95

All Time High

CHF38.40